High resection rates of colorectal liver metastases after standardized follow-up and multimodal management: an outcome study within the COLOFOL trial

Peter Scherman; Pernilla Hansdotter; Erik Holmberg; Frank Viborg Mortensen; Sune H. Petersen; Magnus Rizell; Peter Naredi; Ingvar Syk; COLOFOL study group; Jesper Dan Nielsen

doi:10.1016/j.hpb.2023.03.003

High resection rates of colorectal liver metastases after standardized follow-up and multimodal management: an outcome study within the COLOFOL trial

Peter Scherman^*, Pernilla Hansdotter, Erik Holmberg, Frank Viborg Mortensen, Sune H. Petersen, Magnus Rizell, Peter Naredi, Ingvar Syk, COLOFOL study group, Jesper Dan Nielsen (Member of study group)

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

3 Citations (Scopus)

28 Downloads (Pure)

Abstract

Background: Outcome after colorectal liver metastases (CRLM) resection has improved over time, despite increased resection rates. Hence, it's crucial to identify all patients possible to treat with curative intent. The objectives of this study were to map recurrence pattern, treatment strategy and survival depending on treatment and follow-up strategy.

Methods: In the COLOFOL-trial, patients with radically resected stage II-III colorectal cancer were randomized to high-frequency (6, 12, 18, 24 and 36 months; HF) or low-frequency (12 and 36 months; LF) follow-up. In this study, all CRLM within 5 years were identified and medical files scrutinized. Overall survival (OS) was analysed in uni- and multivariable analyses. Primary endpoint was 5-year OS.

Results: Of 2442 patients, 235 (9.6%) developed metachronous CRLM of which 123 (52.3%) underwent treatment with curative intent, resulting in 5-year OS of 58%. Five-year OS for patients with CRLM was 43% after HF versus 24% after LF. The survival benefit was confirmed for HF 8 years from resection of the primary tumour, HR 0.63 (CI 0.46-0.85).

Conclusion: A high proportion of metachronous CRLM was possible to treat with curative intent, yielding high survival rates. More intense follow-up after colorectal cancer resection might be of value in high-risk patients.

Original language	English
Journal	H P B
Volume	25
Issue number	7
Pages (from-to)	766-774
Number of pages	9
ISSN	1365-182X
DOIs	https://doi.org/10.1016/j.hpb.2023.03.003
Publication status	Published - Jul 2023

Bibliographical note

Access to Document

10.1016/j.hpb.2023.03.003Licence: CC BY-NC-ND 4.0

Open Access articleFinal published version, 461 KBLicence: CC BY-NC-ND 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Scherman, P., Hansdotter, P., Holmberg, E., Viborg Mortensen, F., Petersen, S. H., Rizell, M., Naredi, P., Syk, I., COLOFOL study group, & Nielsen , J. D. (2023). High resection rates of colorectal liver metastases after standardized follow-up and multimodal management: an outcome study within the COLOFOL trial. H P B, 25(7), 766-774. https://doi.org/10.1016/j.hpb.2023.03.003

@article{2a13b7e58c2e425bae3e17c83b91c959,

title = "High resection rates of colorectal liver metastases after standardized follow-up and multimodal management: an outcome study within the COLOFOL trial",

abstract = "Background: Outcome after colorectal liver metastases (CRLM) resection has improved over time, despite increased resection rates. Hence, it's crucial to identify all patients possible to treat with curative intent. The objectives of this study were to map recurrence pattern, treatment strategy and survival depending on treatment and follow-up strategy.Methods: In the COLOFOL-trial, patients with radically resected stage II-III colorectal cancer were randomized to high-frequency (6, 12, 18, 24 and 36 months; HF) or low-frequency (12 and 36 months; LF) follow-up. In this study, all CRLM within 5 years were identified and medical files scrutinized. Overall survival (OS) was analysed in uni- and multivariable analyses. Primary endpoint was 5-year OS.Results: Of 2442 patients, 235 (9.6%) developed metachronous CRLM of which 123 (52.3%) underwent treatment with curative intent, resulting in 5-year OS of 58%. Five-year OS for patients with CRLM was 43% after HF versus 24% after LF. The survival benefit was confirmed for HF 8 years from resection of the primary tumour, HR 0.63 (CI 0.46-0.85).Conclusion: A high proportion of metachronous CRLM was possible to treat with curative intent, yielding high survival rates. More intense follow-up after colorectal cancer resection might be of value in high-risk patients.",

author = "Peter Scherman and Pernilla Hansdotter and Erik Holmberg and {Viborg Mortensen}, Frank and Petersen, {Sune H.} and Magnus Rizell and Peter Naredi and Ingvar Syk and {COLOFOL study group} and Nielsen, {Jesper Dan}",

year = "2023",

month = jul,

doi = "10.1016/j.hpb.2023.03.003",

language = "English",

volume = "25",

pages = "766--774",

journal = "H P B",

issn = "1365-182X",

publisher = "Elsevier",

number = "7",

}

Scherman, P, Hansdotter, P, Holmberg, E, Viborg Mortensen, F, Petersen, SH, Rizell, M, Naredi, P, Syk, I, COLOFOL study group & Nielsen , JD 2023, 'High resection rates of colorectal liver metastases after standardized follow-up and multimodal management: an outcome study within the COLOFOL trial', H P B, vol. 25, no. 7, pp. 766-774. https://doi.org/10.1016/j.hpb.2023.03.003

TY - JOUR

T1 - High resection rates of colorectal liver metastases after standardized follow-up and multimodal management

T2 - an outcome study within the COLOFOL trial

AU - Scherman, Peter

AU - Hansdotter, Pernilla

AU - Holmberg, Erik

AU - Viborg Mortensen, Frank

AU - Petersen, Sune H.

AU - Rizell, Magnus

AU - Naredi, Peter

AU - Syk, Ingvar

AU - COLOFOL study group

A2 - Nielsen , Jesper Dan

PY - 2023/7

Y1 - 2023/7

N2 - Background: Outcome after colorectal liver metastases (CRLM) resection has improved over time, despite increased resection rates. Hence, it's crucial to identify all patients possible to treat with curative intent. The objectives of this study were to map recurrence pattern, treatment strategy and survival depending on treatment and follow-up strategy.Methods: In the COLOFOL-trial, patients with radically resected stage II-III colorectal cancer were randomized to high-frequency (6, 12, 18, 24 and 36 months; HF) or low-frequency (12 and 36 months; LF) follow-up. In this study, all CRLM within 5 years were identified and medical files scrutinized. Overall survival (OS) was analysed in uni- and multivariable analyses. Primary endpoint was 5-year OS.Results: Of 2442 patients, 235 (9.6%) developed metachronous CRLM of which 123 (52.3%) underwent treatment with curative intent, resulting in 5-year OS of 58%. Five-year OS for patients with CRLM was 43% after HF versus 24% after LF. The survival benefit was confirmed for HF 8 years from resection of the primary tumour, HR 0.63 (CI 0.46-0.85).Conclusion: A high proportion of metachronous CRLM was possible to treat with curative intent, yielding high survival rates. More intense follow-up after colorectal cancer resection might be of value in high-risk patients.

AB - Background: Outcome after colorectal liver metastases (CRLM) resection has improved over time, despite increased resection rates. Hence, it's crucial to identify all patients possible to treat with curative intent. The objectives of this study were to map recurrence pattern, treatment strategy and survival depending on treatment and follow-up strategy.Methods: In the COLOFOL-trial, patients with radically resected stage II-III colorectal cancer were randomized to high-frequency (6, 12, 18, 24 and 36 months; HF) or low-frequency (12 and 36 months; LF) follow-up. In this study, all CRLM within 5 years were identified and medical files scrutinized. Overall survival (OS) was analysed in uni- and multivariable analyses. Primary endpoint was 5-year OS.Results: Of 2442 patients, 235 (9.6%) developed metachronous CRLM of which 123 (52.3%) underwent treatment with curative intent, resulting in 5-year OS of 58%. Five-year OS for patients with CRLM was 43% after HF versus 24% after LF. The survival benefit was confirmed for HF 8 years from resection of the primary tumour, HR 0.63 (CI 0.46-0.85).Conclusion: A high proportion of metachronous CRLM was possible to treat with curative intent, yielding high survival rates. More intense follow-up after colorectal cancer resection might be of value in high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=85150836501&partnerID=8YFLogxK

U2 - 10.1016/j.hpb.2023.03.003

DO - 10.1016/j.hpb.2023.03.003

M3 - Journal article

C2 - 36967324

SN - 1365-182X

VL - 25

SP - 766

EP - 774

JO - H P B

JF - H P B

IS - 7

ER -

High resection rates of colorectal liver metastases after standardized follow-up and multimodal management: an outcome study within the COLOFOL trial

Abstract

Bibliographical note

Access to Document

AUB Link

Other files and links

Fingerprint

Cite this